Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387753 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2LTA4HPDE7A | |
| SCHEMBL19863554 | 0.93 | PDE7A (0.33) | SMN1; SMN2LTA4HPDE7A | |
| SCHEMBL21222568 | 0.76 | LTA4H (0.34) | LTA4HPDE7A | |
| SCHEMBL13377825 | 0.76 | ALDH1A1 (0.35) | LTA4HPDE7A | |
| SCHEMBL718126 | 0.76 | LTA4H (0.34) | LTA4HPDE7A | |
| SCHEMBL13722593 | 0.76 | LTA4H (0.34) | LTA4HPDE7A | |
| SCHEMBL13377829 | 0.74 | PDE7A (0.32) | LTA4HPDE7A | |
| SCHEMBL15262631 | 0.74 | — | — | |
| SCHEMBL13331607 | 0.73 | LTA4H (0.33) | LTA4HPDE7A | |
| SCHEMBL20323810 | 0.72 | LTA4H (0.34) | LTA4HPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933835-B1 | TETRAHYDRO-PYRROLO[1,2-B]ISOTHIAZOLE 1,1-DIOXIDES AS LFA-1 INHIBITORS | NOVARTIS AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| CN-101282724-A | Pharmaceutically active tetrahydro-pyrrolo [1, 2-B ] isothiazole 1, 1-dioxides | NOVARTIS AG (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-20080242710-A1 | Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides | BAUMANN KARL | 2008-10-02 | — | — | US | disclosed |
| EP-1933835-A1 | PHARMACEUTICALLY ACTIVE TETRAHYDRO-PYRROLO[1,2-B]ISOTHIAZOLE 1,1-DIOXIDES | Novartis AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039616-A1 | PHARMACEUTICALLY ACTIVE TETRAHYDRO-PYRROLO[1,2-B]ISOTHIAZOLE 1,1-DIOXIDES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242710-A1 | Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides | ICAM1, VCAM1, SELPLG | SMN1; SMN2 1445/4885LTA4H 1056/4885PDE7A 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.